Because of the urgent need to vaccinate more people, we’ve explored innovative ways to increase the number of doses of the Pfizer-BioNTech COVID-19 vaccine we’re able to supply this year, and we now believe that we can potentially deliver approximately 2 billion doses by the end of 2021.
To accomplish this, certain modifications of production processes will be required. Pfizer is scaling up manufacturing operations in our Puurs, Belgium manufacturing facility to increase dose availability and output, and, as a result, there will be a temporary impact on some shipments until mid-February in order to quickly enable increased production volumes afterwards.
Pfizer is working closely with all Governments on allocation of doses. While the precise percentage allocation may fluctuate, we anticipate that it will balance out by the end of Q1 2021. Pfizer remains dedicated to helping each country meet the vaccination needs of its citizens without compromising our highest safety and quality standards.